tiprankstipranks

Jon Congleton Insider Profile

4 Followers
Jon Congleton, CEO, Director at Mineralys Therapeutics, Inc., holds 689.32K shares in Mineralys Therapeutics, Inc. (Ticker: MLYS), holds ― shares in Avalyn Pharma Inc (Ticker: AVLN).
tipranks
Jon Congleton

Jon Congleton
Mineralys Therapeutics, Inc. (MLYS)
CEO, Director

Ranked #18,222 out of 107,360 Corporate Insiders

Profitable Transactions

40%
2 out of 5 Profitable Transactions

Average Return

+23.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$21M
100.00%
0.00%
A breakdown of Jon Congleton's holdings

Insider Roles

Mineralys Therapeutics, Inc.
(MLYS)
CEO, Director
Avalyn Pharma Inc
(AVLN)
Director
Roles that Jon Congleton holds in companies

Most Profitable Insider Trade

Stock:
Mineralys Therapeutics, Inc.
(MLYS)
Rating:Informative Buy
Date:Nov 27, 2023 - Nov 27, 2024
Return:+103.50%
The most profitable trade made by Jon Congleton

Jon Congleton's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Mineralys Therapeutics, Inc.
Apr 15, 2026
CEO, Director
Uninformative Sell
421.88K
$20.58M
Avalyn Pharma Inc
Director
List of latest transactions for each holding click on a transaction to see Jon Congleton's performance on stock

Jon Congleton insider profile FAQ

What is the percentage of profitable transactions made by Jon Congleton?
The percentage of profitable transactions made by Jon Congleton is 40%.
    What is the average return per transaction made by Jon Congleton?
    The average return per transaction made by Jon Congleton is 23.10%.
      What stocks does Jon Congleton hold?
      Jon Congleton holds: MLYS, AVLN stocks.
        What was Jon Congleton’s latest transaction?
        Jon Congleton latest transaction was an Uninformative Sell of $421.88K.
          What was Jon Congleton's most profitable transaction?
          Jon Congleton’s most profitable transaction was an Informative Buy of MLYS stock on November 27, 2023. The return on the trade was 103.50%.
            What is Jon Congleton's role in Mineralys Therapeutics, Inc.?
            Jon Congleton's role in Mineralys Therapeutics, Inc. is CEO, Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.